Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL668709

CCn1/c(=N\N=c2\sc3cc(S(=O)(=O)O)ccc3n2CC)sc2cc(S(=O)(=O)O)ccc21.N.N

nearest known ligand 0.47

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.47
NPSR1 Q6W5P4 8/20 0.42
ALDH1A1 P00352 7/20 0.42
TSHR P16473 3/20 0.42
PKM P14618 2/20 0.42
SMN1; SMN2 Q16637 3/20 0.40
KDM4E B2RXH2 6/20 0.39
NPC1 O15118 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
PPARG P37231 1/20 0.38
NCOA2 Q15596 1/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
MAPK1 P28482 1/20 0.38
HPGD P15428 4/20 0.37
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
GAA P10253 2/20 0.37
LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL2319900 1.00 MAPT (0.47) MAPTNPSR1ALDH1A1TSHRPKM
Ammonia Solution, Strong SCHEMBL306103 1.00 MAPT (0.47) MAPTNPSR1ALDH1A1TSHRPKM
Ammonia Solution, Strong SCHEMBL21840 1.00 MAPT (0.47) MAPTNPSR1ALDH1A1TSHRPKM
Ammonia Solution, Strong SCHEMBL21839 1.00 MAPT (0.47) MAPTNPSR1ALDH1A1TSHRPKM
Ammonia Solution, Strong SCHEMBL1883384 1.00 MAPT (0.47) MAPTNPSR1ALDH1A1TSHRPKM
SCHEMBL432548 0.99 MAPT (0.48) MAPTNPSR1ALDH1A1TSHRPKM
SCHEMBL13458992 0.99 MAPT (0.48) MAPTNPSR1ALDH1A1TSHRPKM
SCHEMBL63297 0.99 MAPT (0.48) MAPTNPSR1ALDH1A1TSHRPKM
SCHEMBL14599149 0.99 MAPT (0.48) MAPTNPSR1ALDH1A1TSHRPKM
SCHEMBL7915441 0.99 MAPT (0.48) MAPTNPSR1ALDH1A1TSHRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2258714-B1 IMPROVED ANALYTICAL METHOD FOR THE DETECTION OF OCCULT HEPATITIS C AND CORRESPONDING DIAGNOSIS KIT FUNDACIÓN PARA EL ESTUDIO DE LAS HEPATITIS VIRALES (ES) 2015-02-25 EP claimed
US-5888787-A REACTING AROMATIC COMPOUND HAVING PENDANT METHYL GROUP, MEDIATOR, LACCASE IN PRESENCE OF OXYGEN TO OBTAIN CORRESPONDING ALDEHYDE NORTH CAROLINA STATE UNIVERSITY (US) 1999-03-30 US claimed
CN-122056846-A Yeast microcapsule collagen peptide oral delivery system, preparation method and application 四川大学 2026-05-19 CN disclosed
CN-122005823-A Application of plant-derived exosome as carrier in preparation of targeted colitis treatment medicament 云南民族大学 2026-05-12 CN disclosed
EP-4729572-A1 VISCOSE-BASED BIOFIBER CONTAINING ACTIVE ANTIOXIDANT COMPONENT AND PREPARATION METHOD THEREOF BYHERB FUTURE HEALTH TECHNOLOGY (QINGDAO) CO., LTD. (CN) 2026-04-22 EP disclosed
US-20260103826-A1 VISCOSE-BASED BIOFIBER CONTAINING ACTIVE ANTIOXIDANT COMPONENT AND PREPARATION METHOD THEREOF BYHERB FUTURE HEALTH TECH QINGDAO CO LTD (CN) 2026-04-16 US disclosed
US-12529672-B2 Electrochemical sensor PALINTEST LIMITED (GB) 2026-01-20 US disclosed
EP-3252073-B1 MONOCLONAL ANTIBODY REACTING WITH GLYCOPEPTIDE, AND USE THEREOF SYSMEX CORP (JP) 2026-01-14 EP disclosed
EP-4660629-A1 METHOD FOR DETECTING TRANSTHYRETIN TETRAMER, AND METHOD FOR EVALUATING STABILITY SYSMEX CORPORATION (JP) 2025-12-10 EP disclosed
US-20250369975-A1 METHOD FOR DETECTING TRANSTHYRETIN TETRAMER, AND METHOD FOR EVALUATING STABILITY SYSMEX CORPORATION (JP) 2025-12-04 US disclosed
EP-4217720-B1 ELECTROCHEMICAL SENSOR PALINTEST LTD (GB) 2025-07-30 EP disclosed
EP-0502448-A2 Method of assaying anti-ubiquitin antibody KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-09-09 EP disclosed
EP-0242727-B1 METHOD OF ASSAYING ADENOCARCINOMA ANTIGENS KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-07-22 EP disclosed
EP-0493686-A1 Monoclonal antibodies to glycolipid carbohydrate chains KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-07-08 EP disclosed
US-5126434-A Binding with specific oligopeptide KAO CORPORATION (JP) 1992-06-30 US disclosed
US-5081032-A Cells of hybridomas KYOWA HAKKO KOGYO CO., LTD. (JP) 1992-01-14 US disclosed
EP-0413477-A1 Monoclonal Antibody Kao Corporation (JP) 1991-02-20 EP disclosed
EP-0339632-A2 Method of assaying human cancer antigens KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1989-11-02 EP disclosed
EP-0339633-A2 Anti-human gastric cancer monoclonal antibody KYOWA HAKKO KOGYO CO., LTD. (JP) 1989-11-02 EP disclosed
EP-0235817-A2 Anti-human stomach cancer monoclonal antibody KYOWA HAKKO KOGYO CO., LTD. (JP) 1987-09-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103826-A1 VISCOSE-BASED BIOFIBER CONTAINING ACTIVE ANTIOXIDANT COMPONENT AND PREPARATION METHOD THEREOF GYS1, GYS2, MACF1 MAPT 1066/4885NPSR1 4836/4885ALDH1A1 2318/4885
US-12529672-B2 Electrochemical sensor TPO, TET2, GPX4 MAPT 3402/4885NPSR1 4096/4885ALDH1A1 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.